What is CRISPR Therapeutics's change in other liabilities?

CRISPR Therapeutics (CRSP) reported change in other liabilities of -$199K in Q1 2026.

How has CRISPR Therapeutics's change in other liabilities changed year-over-year?

CRISPR Therapeutics's change in other liabilities increased by 98.1% year-over-year, from -$10.54M to -$199K.

What does change in other liabilities mean?

Change in miscellaneous liabilities affecting operating cash flow.

CRISPR Therapeutics CRSP Change in Other Liabilities

Change in Other Liabilities at other companies

CG OncologyCGON

-$329K—

Cogent Biosciences, Inc.COGT

$29K+480%

BridgeBio PharmaBBIO

$4.62M+56.8%

Krystal Biotech, Inc.KRYS

$1.44M+169%

Spyre Therapeutics, Inc.SYRE

$36K-98.1%

PTC TherapeuticsPTCT

-$2.31M-404%

Other financials

Income statement

See full

Revenue$1.5M+68.6%

Operating income-$130.2M+12.2%

Net income-$122.9M+9.6%

EPS (diluted)-$1.28+19.0%

Balance sheet

See full

Cash & equivalents$423.3M+80.0%

Total debt$787.6M+259%

Total equity$1.8B-0.8%

Total assets$2.7B+25.8%

Cash flow

See full

Operating cash flow-$108.9M-102%

CapEx$504.0K+145%

Free cash flow-$109.4M-102%

Valuation

See full

Market cap$5.33B+56.4%

Enterprise value$5.69B+69.8%

P/S1,298.3×+1,208×

Profitability

See full

Operating margin-15,754.2%-17,253pp

Net margin-13,856.5%-15,058pp

FCF margin-9,777.6%-10,759pp

Returns & leverage

See full

Return on equity-31.2%+43.7pp

Debt / equity0.4×+0.3×

Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingLiabilities.

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's change in other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CRISPR Therapeutics's change in other liabilities?: CRISPR Therapeutics (CRSP) reported change in other liabilities of -$199K in Q1 2026.
How has CRISPR Therapeutics's change in other liabilities changed year-over-year?: CRISPR Therapeutics's change in other liabilities increased by 98.1% year-over-year, from -$10.54M to -$199K.
What does change in other liabilities mean?: Change in miscellaneous liabilities affecting operating cash flow.